BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
0.4510
-0.0053 (-1.16%)
Apr 25, 2025, 11:26 AM EDT - Market open
BioAtla Revenue
In the year 2024, BioAtla had annual revenue of $11.00M.
Revenue (ttm)
$11.00M
Revenue Growth
n/a
P/S Ratio
2.01
Revenue / Employee
$180,328
Employees
61
Market Cap
26.34M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
BCAB News
- 1 day ago - BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 2 days ago - BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 4 weeks ago - BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - BioAtla Cuts 30% of Jobs in Restructuring Effort - Market Watch
- 4 weeks ago - BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress - GlobeNewsWire
- 5 weeks ago - BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings - GlobeNewsWire
- 5 weeks ago - BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025 - GlobeNewsWire
- 7 weeks ago - AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology) - GlobeNewsWire